MiR-129-5p Inhibits Bone Formation Through TCF4

Overview

Journal Front Cell Dev Biol

Specialty Cell Biology

Date 2020 Nov 26

PMID 33240893

Citations 14

Authors

Chong Yin

Ye Tian

Yang Yu

Chaofei Yang

Peihong Su

Yipu Zhao

Xue Wang

Kewen Zhang

Jiawei Pei

Dijie Li

Zhihao Chen

Yan Zhang

Zhiping Miao

Airong Qian

Affiliations

Soon will be listed here.

Abstract

Osteoporosis is a frequently occurring bone disease in middle-aged and aged men and women. However, current therapies on this disease are still not ideal. MicroRNAs (miRNAs) are a class of endogenous non-protein-coding RNA with a length of 18-25 nucleotides. miRNAs have been identified as important regulators for development, metabolism, carcinogenesis, and bone formation. miR-129-5p has been reported as a regulator of cancer and neuroscience, whereas studies about its function on bone formation is still limited. In this study, we investigated the function and mechanism of miR-129-5p on osteoblast differentiation and bone formation. We have assessed the expression of miRNAs in bone mesenchymal stem cells from aging and menopause osteoporosis C57BL6 mice. The expression of miR-129-5p was altered in all osteoporosis models. Besides, the expression of miR-129-5p was negatively correlated with osteoblastic differentiation markers in the femur tissues of C57BL/6 mice of different ages. We further demonstrated that overexpression of miR-129-5p inhibited osteoblast differentiation in MC3T3-E1 cell line, as well as bone formation of C57BL/6 mice. On the other hand, down-regulation of miR-129-5p enhanced osteoblast differentiation and bone formation. We also found that miR-129-5p inhibited Wnt/β-catenin pathway in osteoblast. The target gene of miR-129-5p has been forecasted and proved as . We further found that plasmid containing 3' UTR sequence enhanced osteoblast differentiation, as well as Wnt/β-catenin pathway in MC3T3-E1 cells. To further investigate the rescue effect of miR-129-5p inhibitor, we manufactured bioengineered novel recombinant miR-129-5p inhibitor through system and then tested its function. The results showed that the novel recombinant miR-129-5p inhibitor promoted osteoblast differentiation and greatly ameliorated menopause osteoporosis in C57BL6 mice. In conclusion, we have discovered miR-129-5p as an inhibitor of bone formation. miR-129-5p inhibited downstream transcription factors of Wnt/β-catenin pathway through targeting . Moreover, novel recombinant miR-129-5p inhibitor showed rescue effect on osteoporosis. This study has revealed a new mechanism of osteogenic differentiation and provided novel therapeutic strategies for treatment of skeletal disorders.

Citing Articles

An Andrias davidianus derived composite hydrogel with enhanced antibacterial and bone repair properties for osteomyelitis treatment.

Yin C, Deng M, Yu J, Chen Y, Zheng K, Huang Y Sci Rep. 2024; 14(1):24626.

PMID: 39426986 PMC: 11490572. DOI: 10.1038/s41598-024-75997-8.

Wnt/β-catenin signaling components and mechanisms in bone formation, homeostasis, and disease.

Hu L, Chen W, Qian A, Li Y Bone Res. 2024; 12(1):39.

PMID: 38987555 PMC: 11237130. DOI: 10.1038/s41413-024-00342-8.

Single-Cell Integration of BMD GWAS Results Prioritize Candidate Genes Influencing Age-Related Bone Loss.

Doolittle M, Khosla S, Saul D JBMR Plus. 2023; 7(10):e10795.

PMID: 37808401 PMC: 10556272. DOI: 10.1002/jbm4.10795.

A novel recombinant ORF7-siRNA delivered by flexible nano-liposomes inhibits varicella zoster virus infection.

Pei J, Tian Y, Ye W, Han J, Dang Y, Cheng T Cell Biosci. 2023; 13(1):167.

PMID: 37700336 PMC: 10496174. DOI: 10.1186/s13578-023-01108-1.

Myocardial fibrosis and calcification are attenuated by microRNA-129-5p targeting Asporin and Sox9 in cardiac fibroblasts.

Medzikovic L, Aryan L, Ruffenach G, Li M, Savalli N, Sun W JCI Insight. 2023; 8(9).

PMID: 37154157 PMC: 10243800. DOI: 10.1172/jci.insight.168655.

References

Ushiku C, Adams D, Jiang X, Wang L, Rowe D . Long bone fracture repair in mice harboring GFP reporters for cells within the osteoblastic lineage. J Orthop Res. 2010; 28(10):1338-47. DOI: 10.1002/jor.21105. View

Zuo B, Zhu J, Li J, Wang C, Zhao X, Cai G . microRNA-103a functions as a mechanosensitive microRNA to inhibit bone formation through targeting Runx2. J Bone Miner Res. 2014; 30(2):330-45. DOI: 10.1002/jbmr.2352. View

Cao Z, Moore B, Wang Y, Peng X, Lappe J, Recker R . MiR-422a as a potential cellular microRNA biomarker for postmenopausal osteoporosis. PLoS One. 2014; 9(5):e97098. PMC: 4018259. DOI: 10.1371/journal.pone.0097098. View

Lai E . Micro RNAs are complementary to 3' UTR sequence motifs that mediate negative post-transcriptional regulation. Nat Genet. 2002; 30(4):363-4. DOI: 10.1038/ng865. View

Gennari L, Rotatori S, Bianciardi S, Nuti R, Merlotti D . Treatment needs and current options for postmenopausal osteoporosis. Expert Opin Pharmacother. 2016; 17(8):1141-52. DOI: 10.1080/14656566.2016.1176147. View

Almeida M, Han L, Martin-Millan M, OBrien C, Manolagas S . Oxidative stress antagonizes Wnt signaling in osteoblast precursors by diverting beta-catenin from T cell factor- to forkhead box O-mediated transcription. J Biol Chem. 2007; 282(37):27298-27305. DOI: 10.1074/jbc.M702811200. View

Bartel D . MicroRNAs: target recognition and regulatory functions. Cell. 2009; 136(2):215-33. PMC: 3794896. DOI: 10.1016/j.cell.2009.01.002. View

Zeng Z, Liu Y, Zheng W, Liu L, Yin H, Zhang S . MicroRNA-129-5p alleviates nerve injury and inflammatory response of Alzheimer's disease via downregulating SOX6. Cell Cycle. 2019; 18(22):3095-3110. PMC: 6816367. DOI: 10.1080/15384101.2019.1669388. View

Li X, Tian Y, Tu M, Ho P, Batra N, Yu A . Bioengineered miR-27b-3p and miR-328-3p modulate drug metabolism and disposition the regulation of target ADME gene expression. Acta Pharm Sin B. 2019; 9(3):639-647. PMC: 6543075. DOI: 10.1016/j.apsb.2018.12.002. View

10.

Li C, Talele N, Boo S, Koehler A, Knee-Walden E, Balestrini J . MicroRNA-21 preserves the fibrotic mechanical memory of mesenchymal stem cells. Nat Mater. 2016; 16(3):379-389. DOI: 10.1038/nmat4780. View

11.

Chen Q, Wang W, Zeng S, Urayama S, Yu A . A general approach to high-yield biosynthesis of chimeric RNAs bearing various types of functional small RNAs for broad applications. Nucleic Acids Res. 2015; 43(7):3857-69. PMC: 4402540. DOI: 10.1093/nar/gkv228. View

12.

Ho P, Duan Z, Batra N, Jilek J, Tu M, Qiu J . Bioengineered Noncoding RNAs Selectively Change Cellular miRNome Profiles for Cancer Therapy. J Pharmacol Exp Ther. 2018; 365(3):494-506. PMC: 5931433. DOI: 10.1124/jpet.118.247775. View

13.

Wang X, Guo B, Li Q, Peng J, Yang Z, Wang A . miR-214 targets ATF4 to inhibit bone formation. Nat Med. 2012; 19(1):93-100. DOI: 10.1038/nm.3026. View

14.

Huang L, Jin J, Deighan P, Kiner E, McReynolds L, Lieberman J . Efficient and specific gene knockdown by small interfering RNAs produced in bacteria. Nat Biotechnol. 2013; 31(4):350-6. PMC: 3622153. DOI: 10.1038/nbt.2537. View

15.

Li C, Cheng P, Liang M, Chen Y, Lu Q, Wang J . MicroRNA-188 regulates age-related switch between osteoblast and adipocyte differentiation. J Clin Invest. 2015; 125(4):1509-22. PMC: 4396470. DOI: 10.1172/JCI77716. View

16.

Zhang P, Li J, Song Y, Wang X . MiR-129-5p Inhibits Proliferation and Invasion of Chondrosarcoma Cells by Regulating SOX4/Wnt/β-Catenin Signaling Pathway. Cell Physiol Biochem. 2017; 42(1):242-253. DOI: 10.1159/000477323. View

17.

Li G, Xie J, Wang J . Tumor suppressor function of miR-129-5p in lung cancer. Oncol Lett. 2019; 17(6):5777-5783. PMC: 6507349. DOI: 10.3892/ol.2019.10241. View

18.

Ponchon L, Beauvais G, Nonin-Lecomte S, Dardel F . A generic protocol for the expression and purification of recombinant RNA in Escherichia coli using a tRNA scaffold. Nat Protoc. 2009; 4(6):947-59. DOI: 10.1038/nprot.2009.67. View

19.

Georgiou K, Hui S, Xian C . Regulatory pathways associated with bone loss and bone marrow adiposity caused by aging, chemotherapy, glucocorticoid therapy and radiotherapy. Am J Stem Cells. 2013; 1(3):205-24. PMC: 3636730. View

20.

Jabbar S, Drury J, Fordham J, Datta H, Francis R, Tuck S . Osteoprotegerin, RANKL and bone turnover in postmenopausal osteoporosis. J Clin Pathol. 2011; 64(4):354-7. DOI: 10.1136/jcp.2010.086595. View